Executive Summary: Therapeutic Application of GLP-1 Receptor Agonists in Obesity Management
Executive Summary The landscape of obesity management has undergone a paradigm shift with the introduction and FDA approval of potent Glucagon-like Peptide-1 (GLP-1) receptor agonists (e.g., semaglutide) and dual GIP/GLP-1 agonists (e.g., tirzepatide). Originally developed for Type 2 Diabetes management, these agents mimic the action of endogenous incretin hormones. Recent high-impact research demonstrates their efficacy…